Pheochromocytoma - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 66 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pheochromocytoma - Pipeline Review, H2 2016, provides an overview of the Pheochromocytoma (Oncology) pipeline landscape.

Pheochromocytoma is a rare, usually non-cancerous (benign) tumor that develops in cells in the center of an adrenal gland. Symptoms include high blood pressure, severe headache, tremors, shortness of breath and constipation. Risk factors include multiple endocrine neoplasia type II (MEN), Von Hippel-Lindau disease (VHL) and neurofibromatosis 1 (NF1).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pheochromocytoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Pheochromocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pheochromocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pheochromocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 4 and 2 respectively for Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively for Pheochromocytoma.

Pheochromocytoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pheochromocytoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Pheochromocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pheochromocytoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pheochromocytoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pheochromocytoma (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pheochromocytoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pheochromocytoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Pheochromocytoma Overview 6
Therapeutics Development 7
Pipeline Products for Pheochromocytoma - Overview 7
Pipeline Products for Pheochromocytoma - Comparative Analysis 8
Pheochromocytoma - Therapeutics under Development by Companies 9
Pheochromocytoma - Therapeutics under Investigation by Universities/Institutes 10
Pheochromocytoma - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Pheochromocytoma - Products under Development by Companies 13
Pheochromocytoma - Products under Investigation by Universities/Institutes 14
Pheochromocytoma - Companies Involved in Therapeutics Development 15
Exelixis, Inc. 15
MediaPharma s.r.l. 16
Pfizer Inc. 17
Progenics Pharmaceuticals, Inc. 18
Valeant Pharmaceuticals International, Inc. 19
Pheochromocytoma - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 28
cabozantinib s-malate - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
iobenguane sulfate I 131 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
LMP-400 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
metyrosine - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
MPBF-001 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
S-43126 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
sunitinib malate - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Pheochromocytoma - Dormant Projects 59
Pheochromocytoma - Product Development Milestones 60
Featured News & Press Releases 60
Dec 03, 2015: Progenics Pharmaceuticals Achieves Target Enrollment in its Phase 2b Pivotal Trial of Azedra 60
Oct 12, 2015: Phase 2 Dosimetry Data for Progenics' AZEDRA Presented at EANM Congress 2015 60
Jul 28, 2015: Progenics Announces Breakthrough Therapy Designation for Azedra in Pheochromocytoma and Paraganglioma 61
Mar 02, 2015: Progenics Pharmaceuticals Announces Presentation at ENDO 2015 61
Jan 23, 2015: Progenics Pharmaceuticals Relaunches Pivotal Trial of AZEDRA in Pheochromocytoma 61
Sep 22, 2014: Progenics Pharmaceuticals Presents Long Term Follow-Up of Pivotal Phase 2 Trial of Azedra in Malignant Pheochromocytoma 62
Apr 01, 2014: Progenics Pharmaceuticals and Centre for Probe Development and Commercialization Announce Agreement to Manufacture Targeted Radiotherapeutic Candidate for Ultra-Orphan Indications 63
Nov 25, 2013: Progenics Pharmaceuticals Relaunching Registrational Trial of Azedra to Treat Pheochromocytomas 63
Appendix 65
Methodology 65
Coverage 65
Secondary Research 65
Primary Research 65
Expert Panel Validation 65
Contact Us 65
Disclaimer 66

List of Tables

Number of Products under Development for Pheochromocytoma, H2 2016 7
Number of Products under Development for Pheochromocytoma - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Products under Investigation by Universities/Institutes, H2 2016 14
Pheochromocytoma - Pipeline by Exelixis, Inc., H2 2016 15
Pheochromocytoma - Pipeline by MediaPharma s.r.l., H2 2016 16
Pheochromocytoma - Pipeline by Pfizer Inc., H2 2016 17
Pheochromocytoma - Pipeline by Progenics Pharmaceuticals, Inc., H2 2016 18
Pheochromocytoma - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016 19
Assessment by Monotherapy Products, H2 2016 20
Number of Products by Stage and Target, H2 2016 22
Number of Products by Stage and Mechanism of Action, H2 2016 24
Number of Products by Stage and Route of Administration, H2 2016 26
Number of Products by Stage and Molecule Type, H2 2016 27
Pheochromocytoma - Dormant Projects, H2 2016 59